Gilead Sciences shares rose 8.1% this afternoon to a price of $119.24. The stock is still trading within range of its average target price of $120.32, and over the last 52 weeks, it has recorded a 49.7% performance. Analysts have given the Large-Cap Biotechnology stock target prices ranging from $91.0 to $143.0 dollars per share, with an average rating of buy.
Gilead Sciences's short interest -- meaning the percentage of the share float that is being shorted -- is lower than average at 1.8%. The stock's short ratio is 2.8. At 0.1%, the company's rate of insider ownership does not indicate that management is heavily invested in the corporation.
Another number to watch is the company's rate of institutional share ownership, which now stands at 89.9%. In conclusion, we believe there is mixed market sentiment regarding Gilead Sciences.
Institutions Invested in Gilead Sciences
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2025-03-31 | Vanguard Group Inc | 9% | 117,470,825 | $14,007,220,922 |
| 2025-03-31 | Blackrock Inc. | 9% | 116,104,572 | $13,844,308,917 |
| 2025-03-31 | State Street Corporation | 5% | 59,523,675 | $7,097,602,879 |
| 2025-03-31 | FMR, LLC | 5% | 58,542,842 | $6,980,648,355 |
| 2025-03-31 | Capital Research Global Investors | 4% | 54,610,370 | $6,511,740,402 |
| 2025-03-31 | Capital World Investors | 4% | 53,547,901 | $6,385,051,600 |
| 2025-03-31 | Dodge & Cox Inc | 3% | 32,694,791 | $3,898,526,808 |
| 2025-03-31 | Geode Capital Management, LLC | 2% | 28,480,147 | $3,395,972,667 |
| 2025-03-31 | Wellington Management Group, LLP | 2% | 27,358,967 | $3,262,283,166 |
| 2025-03-31 | Morgan Stanley | 2% | 19,800,980 | $2,361,068,812 |
